Complex | |
AACDB_ID: | 1995 |
PDBID: | 6A3W |
Chains: | JK_L |
Organism: | Homo sapiens |
Method: | XRD |
Resolution (Å): | 2.00 |
Reference: | 10.1016/j.celrep.2018.09.073 |
Antibody | |
Antibody: | utomilumab Fv |
Antibody mutation: | No |
INN (Clinical Trial): | Utomilumab(Phase-II) |
Antigen | |
Antigen: | Tumor necrosis factor receptor superfamily member 9 (CD137) |
Antigen mutation: | No |
Durg Target: | Q07011 |
Antibody
Heavy Chain: J
Mutation: NULL
>6A3W_J|Chain A, D, G, J|utomilumab VH|Homo sapiens (9606) EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSS |
Light Chain: K
Mutation: NULL
>6A3W_K|Chain B, E, H, K|utomilumab VL|Homo sapiens (9606) MSYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL |
Antigen
Chain: L
Mutation: NULL
>6A3W_L|Chain C, F, I, L|Tumor necrosis factor receptor superfamily member 9|Homo sapiens (9606) LQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQRTCDICRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCSMCEQDCKQGQELTKKGCKDCCFGTFNDQKRGICRPWTNCSLDGKSVLVNGTKERDVVCGPSPADLSPGASSVTPPAPAREHHHHHH |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
J: GLU1 THR31 TYR32 TRP33 LYS50 TYR52 ASP55 TYR57 ARG98 TYR100 ILE102 ASP104 TYR105 K: GLY29 ASP30 GLN31 TYR32 LEU46 TYR49 GLN50 ASP51 ARG54 PRO55 SER56 ASN66 TYR91 GLY93 SER96 L: ARG66 VAL71 PHE72 CYS94 LEU95 GLY96 ALA97 SER100 MET101 CYS102 GLU103 GLN104 GLU111 LEU112 THR113 LYS114 LYS115 PHE125 GLN128 ARG130 GLY131 ILE132 ARG134 PRO135 THR137 ASP155 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)